Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Amivantamab by Johnson & Johnson for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase II for Recurrent Head And Neck Squamous...
Amivantamab by Johnson & Johnson for Metastatic Ovarian Cancer: Likelihood of Approval
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Metastatic Ovarian Cancer. According to...
Amivantamab by Johnson & Johnson for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According...
Amivantamab by Johnson & Johnson for Metastatic Breast Cancer: Likelihood of Approval
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Metastatic Breast Cancer. According to...
Amivantamab by Johnson & Johnson for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According...
Amivantamab by Johnson & Johnson for Solid Tumor: Likelihood of Approval
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase III for Solid Tumor. According to GlobalData,...
Amivantamab by Johnson & Johnson for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According...